Search Results
Your search for can matches 13815 pages
Showing 9251 - 9300HOX Gene Expression in Ovarian Cancer Offers Novel Prognostic Significance
A new study has identified a gene signature that predicts poor survival from ovarian cancer. The study also identified genes which help the cancer develop resistance to chemotherapy—offering a new route to help tackle the disease. The study, published by Kelly et al in the International...
Relapse of Leukemia After Bone Marrow Transplantation: Cytomegalovirus Infection Has No Protective Effect
Recent studies on a small number of patients with leukemia treated with bone marrow transplantation have suggested that the presence of the common cytomegalovirus (CMV) in patients or their donors may protect against relapse or even death after the transplant. A large international study published...
New: ASCO Answers Guide to Non–Small Cell Lung Cancer
The new ASCO Answers Guide to non–small cell lung cancer replaces the previous guide to general lung cancer. It is designed just for patients newly diagnosed with non–small cell lung cancer to help them better understand the disease and their treatment options. It includes information on treatment, ...
Clinical Trials Actively Recruiting Patients With Cardiotoxicity Resulting From Treatment
Observational Study Title: Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors Study Type: Observational Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center Purpose: To study whether strain and...
What’s Driving the Rising Rates of Colorectal Cancer in Young Adults?
The study statistics are alarming—and perplexing. According to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) colorectal cancer registry, colon cancer incidence among young adults aged 20 to 34 is expected to increase 90% by 2030, and the incidence of rectosigmoid...
Personalized Dosimetry Optimizes Radiotherapy Dose in Patients With Neuroendocrine Tumors
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging methodology that allows the increase of the radiotherapy dose to the tumor while protecting vulnerable vital organs.1 The delicate balance of administering the...
Computed Tomography–Based Lean Body Mass Calculations May Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body composition...
Novel Approach to PET/CT Imaging May Predict Location and Extent of Primary Prostate Cancer
With surgical removal at the front line of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society...
Expert Point of View: Charles Ryan, MD
“These are important data. It is safe to envision a future where atezolizumab [Tecentriq] can be used first-line. These were cisplatin-ineligible patients, and many patients fall into this category, especially the elderly. Platinum-ineligibility is a big problem due to comorbidities,” explained...
New Standard of Care Emerges for Anaplastic Glioma Without 1p/19q Codeletion
Adjuvant temozolomide, after radiotherapy, improves overall survival in patients with grade 3 anaplastic glioma without 1p/19q codeletion, according to a phase III EORTC (European Organization for Research and Treatment of Cancer) study presented at the 2016 ASCO Annual Meeting.1 “We were...
CAR T-Cell Dose Refinement May Reduce Cytokine-Release Syndrome in Patients With Advanced Acute Lymphoblastic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy has been effective in adults and children with advanced acute lymphoblastic leukemia (ALL), but along with efficacy, the treatment can stimulate cytokine-release syndrome, which can be deadly if it goes unrecognized and untreated. Adjusting the dose...
Richard Pazdur, MD, Named Acting Director of FDA’s Oncology Center of Excellence
U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement June 29, 2016, regarding the appointment of Richard Pazdur, MD, as the Acting Director of the FDA Oncology Center of Excellence. Dr. Pazdur is currently Director of the Office of Oncology...
Expert Point of View: Stephen K.L. Chia, MD
Stephen K.L. Chia, MD, of the British Columbia Cancer Agency, Vancouver, discussed two of these neoadjuvant breast cancer studies at the ASCO Annual Meeting. In the current landscape for neoadjuvant therapy in HER2-positive disease, said Dr. Chia, the NeoSphere, TRYPHAENA, KRISTINE, and I-SPY 2...
Pertuzumab-Containing Regimens Compared for Neoadjuvant Treatment in Early Breast Cancer
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzumab (Perjeta), or TCH+P, than with ado-trastuzumab emtansine (Kadcyla) plus pertuzumab, or T-DM1+P,...
Kaposi Sarcoma–Associated Herpesvirus Mimics Host Signal to Drive Cell Growth, Protein Production
In a study report published by Bhatt et al in Proceedings of the National Academy of Sciences, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center explained how a type of herpesvirus uses mimicry to trick the host cell to produce proteins the virus needs and...
Analysis of Cerebrospinal Fluid for D-2-Hydroxyglutarate May Detect Malignant Brain Tumors Nonsurgically
When a brain tumor is suspected, its presence is usually confirmed by anatomic imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). But through imaging, not much about the tumor molecularly can be learned. Surgery and a biopsy are necessary to get a glimpse of the cancer...
The Age of the Atomic Hematologists/Oncologists
Every longstanding culture has ages: The Minoans were followed by the Mycenaeans and, later, the Hellenistic peoples. And so it is with hematology/oncology. A descriptive age dominated predominately by histopathologists was followed by an age of experimentalists. Development of the atomic bombs...
Assessment of Fitness, Function, and Quality of Life Essential in Treatment of Older Patients With CLL
Significant progress has been made in the past 2 decades in the care of patients with chronic lymphocytic leukemia (CLL). Recently, the therapeutic armamentarium has expanded for such patients with the introduction of new targeted agents. CLL is predominantly a disease of the elderly, with a...
Combination of Nivolumab and Ipilimumab Moves Forward in NSCLC
How best to combine new immunotherapies is a burning question in oncology. A new study in the CheckMate series suggests that nivolumab (Opdivo) and ipilimumab (Yervoy) can be safely and effectively combined as first-line treatment of advanced non–small cell lung cancer (NSCLC),1 but further study...
Approximately 20% of Older Women With Early Breast Cancer Experience Some Form of Functional Decline After Treatment
In a study of older women with newly diagnosed stage I to III breast cancer, approximately 1 in 5 lost the ability to complete some of the basic tasks necessary for independent living within 1 year of initiating treatment. The study also found that a simple survey can help identify which women are...
Primary Care Visits Result in More Colorectal Cancer Screening, Better Follow-up
People who visit their primary care physicians are more likely to get potentially life-saving colon cancer screenings and follow-up on abnormal stool blood test results—even in health systems that heavily promote mail-in home stool blood tests that don’t require a doctor visit, a study...
Women With High-Grade Cervical Intraepithelial Neoplasia Have Long-Term Increased Risk for HPV-Related Anal, Vulvar, and Vaginal Cancers
Although high-risk human papillomavirus (HPV) is essential for developing high-grade cervical intraepithelial neoplasia (CIN2 and CIN3) and has also been associated with noncervical anogenital cancers, little is known about the long-term risk for anal, vulvar, and vaginal cancer following a...
Richard Pazdur, MD, Named Acting Director of the FDA Oncology Center of Excellence
U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement today regarding the appointment of the Acting Director of the FDA Oncology Center of Excellence. “The FDA is honored to be an integral part of the Vice President’s National Cancer...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
On June 28, the U.S. Food and Drug Administration (FDA) approved a fixed-dose combination of sofosbuvir, 400 mg, plus velpatasvir, 100 mg (Epclusa) to treat adult patients with chronic hepatitis C virus (HCV) either with or without cirrhosis. For patients with moderate to severe cirrhosis...
ASCO Outlines Opposition to Medicare Part B Demo for Senate Finance Hearing
ASCO voiced its strong opposition to the proposed Medicare Part B demonstration project in comments submitted on June 28 for the U.S. Senate Finance Committee hearing, “Examining the Proposed Medicare Part B Drug Demonstration.” ASCO underscored the urgent need to advance a fairer...
CAP, IASLC, and AMP Seek Public Comments on Revised Lung Cancer Molecular Testing Guideline
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of...
Influence of Microbiota of Breast Tissue on the Development of Cancers
Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, according to Gregor Reid, PhD, of the Lawson Health Research Institute, and...
Lawrence O. Gostin, JD, LLD, Appointed to National Cancer Advisory Board
President Barack Obama has tapped Lawrence O. Gostin, JD, LLD, Georgetown University Professor and Faculty Director of the O’Neill Institute for National and Global Health Law at Georgetown Law, to serve as a member of the National Cancer Advisory Board (NCAB). He will serve a 6-year term. The 18 ...
Precision Medicine Clinical Trial for Metastatic Pancreatic Cancer Now Open at Multiple Sites
The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country. Patients who have been treated with one round of chemotherapy for...
Use Questions From Patients to Help Them Make Informed Treatment Decisions
Recent reports about treatment options for patients with ductal carcinoma in situ, and the ensuing debate and comments played out in the media, may prompt increased questions from patients. A review summarizing data about these treatment options concluded that surgery and radiation therapy “remain...
Surgery and Radiation Therapy Remain Standard of Care for Managing Ductal Carcinoma in Situ
A review of more than 50 studies (many randomized controlled trials) concluded that surgery and radiation therapy “remain standard-of-care treatment options” in the management of ductal carcinoma in situ.1 The review continues the widely reported discussion on managing ductal carcinoma in situ,...
Taubman Prize Jointly Awarded to Suzanne L. Topalian, MD, and Jedd D. Wolchok, MD, PhD, for Groundbreaking Work in Cancer Immunotherapy
Two clinician-scientists whose groundbreaking work has shown how the human body’s own immune system can fend off cancer will share the 2016 $100,000 Taubman Prize for Excellence in Translational Medical Science, the University of Michigan’s A. Alfred Taubman Medical Research Institute announced....
Something Happened
Over the years, my patients have been my most important teachers. I’ve learned so much from them about human nature and the resilience of the human spirit. When my time came to pass through the fire and confront the same challenges they and their families face so bravely and with such compassion, ...
Inside Knowledge From a Cancer Survivor
Curtis Pesmen is a well-regarded writer who has authored six books of nonfiction as well as numerous articles for publications such as Esquire and The New York Times. He also has served as founding editor of LIVESTRONG Quarterly and often speaks and writes on patient advocacy. Shortly after...
St. Jude Children’s Research Hospital Names Michael Dyer, PhD, Chair of Developmental Neurobiology
St. Jude Children’s Research Hospital has named Michael Dyer, PhD, Chair of the Department of Developmental Neurobiology. “A true visionary in his field, Dr. Dyer is a remarkable scientist who has worked tirelessly to unravel some of the long-held mysteries of childhood cancer,” said James R....
Moonshot Program for … Compassion
A 65-year-old patient with widely metastatic pancreatic cancer was emergently transferred to our facility in the early hours of the morning with free air suggestive of a perforated viscus. The patient is from a small town several hundred miles away from our academic center, which can be quite...
Katherine L. Nathanson, MD, Receives AACR’s Frohlich Visiting Professorship
Katherine L. Nathanson, MD, Professor of Medicine in the Division of Translational Medicine and Human Genetics at the Perelman School of Medicine of the University of Pennsylvania, has received the 2015 Frohlich Visiting Professorship through the American Association for Cancer Research (AACR)....
Vanguard Practices Support Sharing Big Data With CancerLinQ™
CancerLinQ LLC, recently announced that it has completed agreements with 36 vanguard oncology practices from around the country to begin implementing the tool. According to physicians at the vanguard practices, gaining access to the experience of oncology practices across the country motivated...
Meet Thomas G. Roberts, Jr, MD
Thomas G. Roberts, Jr, MD, is Managing Member at Farallon Capital Management, LLC and Chair of the Conquer Cancer Foundation of ASCO Board of Directors and Executive Committee. What led you to oncology prior to your career in finance? TGR: As an intern at Massachusetts General Hospital, I was...
Expanded Content on Geriatric Oncology
Cancer.Net has newly updated information specifically for older patients with cancer and is expanding coverage of this segment of cancer care across the site. Direct your patients and their caregivers to cancer.net/olderadults to find articles on aging and cancer, making treatment decisions, and...
Clinical Conversations: Attendee Questions From the Cancer Survivorship Symposium
The inaugural Cancer Survivorship Symposium, held in January 2016, drew more than 800 attendees across the cancer-care spectrum—far exceeding the goal of 500 attendees. As a way to continue the discussion from the meeting, several faculty members responded to questions from General Sessions 5 and...
ASCO Endows Young Investigator Award in Honor of Society Founder Jane Cooke Wright, MD
For the first time in ASCO’s history, the Society has endowed its own Young Investigator Award (YIA), illustrating its continued commitment to investing in the future of cancer research. Ongoing support of this kind will ensure that the Conquer Cancer Foundation (CCF), ASCO’s philanthropic arm, is...
Geriatric Patients With Cancer and the Problem of Polypharmacy
Older patients with cancer generally have multiple comorbidities, with each often requiring separate medications. Studies have shown that polypharmacy and inappropriate drug use are prevalent among older cancer patients, leading to an enormous amount of preventable adverse events, many requiring...
Anti–PD-1 Treatment With Pembrolizumab in Gastric/Gastroesophageal Junction Cancers: Who Is Likely to Respond?
Immune checkpoint inhibitors have emerged as one of the most promising new areas of drug development in oncology. Broad activity has been observed for these agents across a spectrum of hematologic malignancies and solid tumors. As reviewed in this issue of The ASCO Post, Muro and colleagues now...
Nivolumab or Ipilimumab Treatment May Increase Risk of Developing Autoimmune Joint and Tissue Disease
Case reports on 13 patients with cancer suggest that patients taking the immunotherapeutics ipilimumab (Yervoy) and nivolumab (Opdivo) may be at higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns...
Tackling the Symptoms of Long-Term Fatigue and Insomnia in Cancer Survivors
Fatigue and sleep disruption are common occurrences for most patients diagnosed with cancer. Simply having a serious physical illness like cancer along with its associated pain, hospitalization, and treatment, as well as the attendant psychological impact, all contribute to the onset of fatigue...
A Conquer Cancer Foundation Award Helps to Launch a Pioneering Study in Liposarcoma
Mark A. Dickson, MD, has been fascinated by science and medicine since he was in high school. After graduating magna cum laude from Harvard University in 1999, Dr. Dickson pursued a medical degree from the College of Physicians and Surgeons at Columbia University in New York. Once he decided on a...
Cervical Cancer Prevention Badly Needed in India
With the advent of the Papanicolaou (Pap) test and population-based screening, along with the development of the human papillomavirus (HPV) vaccine, cervical cancer has become a largely preventable disease for many. However, in India, cervical cancer is a leading cause of cancer mortality. To...
Ixazomib: A Relevant Addition to Myeloma Therapy
In 2015, four new drugs were approved for the treatment of multiple myeloma by the U.S. Food and Drug Administration: panobinostat (Farydak), daratumumab (Darzalex), elotuzumab (Empliciti), and ixazomib (Ninlaro). Of them, the first three are drugs with unique new targets, whereas ixazomib is the...
Medical Decision-Making: At the Heart of Care for Older Patients With Cancer
Although oncology has moved toward a personalized approach to care, medical decision-making within the context of multidisciplinary care has broad public health implications. To shed light on this and other relevant issues, The ASCO Post recently spoke with William Dale, MD, PhD, of the University ...
